Education
About Us
Working with TipRanks
Follow Us
Medrx Co., Ltd. (JP:4586)
:4586
4586 Stock Chart & Stats
Day’s Range― - ―
52-Week Range¥55.00 - ¥199.00
Previous CloseN/A
Volume596.00K
Average Volume (3M)977.61K
Market Cap
¥3.35B
Enterprise Value¥1.92B
Total Cash (Recent Filing)¥1.98B
Total Debt (Recent Filing)¥0.00
Price to Earnings (P/E)―
Beta1.48
Next Earnings
May 09, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-17.52
Shares Outstanding50,695,100
10 Day Avg. Volume1,423,720
30 Day Avg. Volume977,610
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
---
4586 FAQ
What was Medrx Co., Ltd.’s price range in the past 12 months?
Medrx Co., Ltd. lowest stock price was ¥55.00 and its highest was ¥199.00 in the past 12 months.
What is Medrx Co., Ltd.’s market cap?
Medrx Co., Ltd.’s market cap is ¥3.35B.
When is Medrx Co., Ltd.’s upcoming earnings report date?
Medrx Co., Ltd.’s upcoming earnings report date is May 09, 2025 which is in 12 days.
How were Medrx Co., Ltd.’s earnings last quarter?
Medrx Co., Ltd. released its earnings results on Feb 14, 2025. The company reported -¥10.96 earnings per share for the quarter, missing the consensus estimate of N/A by -¥10.96.
Is Medrx Co., Ltd. overvalued?
According to Wall Street analysts Medrx Co., Ltd.’s price is currently Overvalued.
Does Medrx Co., Ltd. pay dividends?
Medrx Co., Ltd. does not currently pay dividends.
What is Medrx Co., Ltd.’s EPS estimate?
Medrx Co., Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Medrx Co., Ltd. have?
Medrx Co., Ltd. has 50,695,100 shares outstanding.
What happened to Medrx Co., Ltd.’s price movement after its last earnings report?
Medrx Co., Ltd. reported an EPS of -¥10.96 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.22%.
Which hedge fund is a major shareholder of Medrx Co., Ltd.?
Currently, no hedge funds are holding shares in JP:4586
---
Company Description
Medrx Co., Ltd.
MedRx Co., Ltd, a pharmaceutical formulation development company, provides pharmaceutical drugs based on the transdermal absorption system in Japan. The company develops medicines based on Ionic liquid transdermal system (ILTS) and Nano-sized Colloid Transdermal System (NCTS); and researches and develops painless transdermal administration system for vaccines, nucleic acid medicines, protein medicines, etc. Its products pipeline includes MRX-4TZT, which is in phase I clinical trials for the treatment of spastic paralysis; MRX-9FLT that is in phase I clinical trials to treat chronic, cancer, and severe pain; and MRX-7MLL and MRX-6LDT that is in pre-clinical trials to treat Alzheimer's disease and chronic pain, as well as MRX-5LBT that has completed the clinical trials for the treatment of postherpetic nerve pain. MedRx Co., Ltd was incorporated in 2002 and is headquartered in Higashikagawa, Japan.
---
Technical Analysis
---